Conditions

Home / Conditions

 

Cancer Vaccine Plus Opdivo Showing Promise in Advanced Prostate Cancer Trial

Cancer Vaccine Plus Opdivo Showing Promise in Advanced Prostate Cancer Trial

A combination of Vaccitech’s experimental vaccine VTP-800 and Opdivo (nivolumab) appears to be a safe and potentially effective treatment for men with metastatic castration resistant prostate cancer (mCRPC), according to early data from a Phase 2a part of clinical trial. The open-label study (NCT03815942), called ADVANCE, may still be recruiting up to 36 patients in the U.K. It is sponsored…

Lundbeck Sharing Data on Failed Idalopirdine Trials with Scientists via C-Path

Lundbeck Sharing Data on Failed Idalopirdine Trials with Scientists via C-Path

Data from Lundbeck’s Phase 2 and 3 clinical trials of idalopirdine in Alzheimer’s patients, will be made available to researchers worldwide through the Critical Path for Alzheimer’s Disease (CPAD) consortium database, held by The Critical Path Institute (C-Path). The Phase 3 studies failed to meet their primary goals of improving cognitive abilities in those given this treatment. C-Path is…

1st Patient Treated in Phase 1 Trial of ATG-019 for Lymphoma, Solid Tumors

1st Patient Treated in Phase 1 Trial of ATG-019 for Lymphoma, Solid Tumors

The first patient has been dosed in Antengene‘s Phase 1 clinical trial investigating the dual inhibitor ATG-019, alone or in combination with niacin extended release, for people with non-Hodgkin’s lymphoma or advanced solid tumors. ATG-019 is being developed as KPT-9274 by Karyopharm Therapeutics, but Antengene acquired its development and commercialization rights in several Asian countries and…

Anticipating Summer Solstice in Support of Alzheimer’s Funding

Anticipating Summer Solstice in Support of Alzheimer’s Funding

It helps to have something on the back burner, something to anticipate in the days, weeks, and months ahead. We need something on which to place our concentration, other than COVID-19. Summer solstice is that thing. Not the day so much, but the annual event surrounding it. Alzheimer’s Association Continues ‘Longest Day’ Since 2012, the…

Bavencio Seen as Ineffective in Phase 3 Head and Neck Cancer Trial

Bavencio Seen as Ineffective in Phase 3 Head and Neck Cancer Trial

A Phase 3 trial of Bavencio (avelumab) in people with squamous cell carcinoma of the head and neck (SCCHN) was ended early due to a lack of effectiveness seen in an interim analysis, the companies that developed and are marketing the treatment announced. Data from the study, named JAVELIN Head and Neck 1oo (NCT02952586), showed that…

Spain Reviewing Trial to Treat COVID-19 Pneumonia With Myeloma Therapy Aplidin

Spain Reviewing Trial to Treat COVID-19 Pneumonia With Myeloma Therapy Aplidin

Madrid-based PharmaMar has submitted the protocol for a Phase 2 trial to the Spanish Medicines and Healthcare Products Agency (AEMPS) to test its multiple myeloma therapy Aplidin (plitidepsin) in people with COVID-19 pneumonia. The trial, named APLICOV, aims to recruit 160 patients across multiple sites in Spain and assess if Aplidin reduces the proportion of…

First Advanced Cancer Patients Dosed With VT1021 in Trial’s Expansion Phase

First Advanced Cancer Patients Dosed With VT1021 in Trial’s Expansion Phase

A Phase 1b/2 trial investigating Vigeo Therapeutics‘ VT1021 as a stand-alone treatment for advanced ovarian cancer and other tumor types has dosed the first patients in its dose expansion stage. Early results are expected later this year. Roughly 75 adults will be enrolled in this stage of the trial (NCT03364400). Besides ovarian cancer, the other groups…

Novel Imaging Tool for Breast Cancer on Display at European Congress of Radiology

Novel Imaging Tool for Breast Cancer on Display at European Congress of Radiology

iCAD Inc. recently announced its latest innovative imaging tool for early detection of breast cancer based on tomosynthesis computer-aided detection (CAD). The technology is on display at the European Congress of Radiology (ECR) in Vienna, Austria, through March 6. According to a study published in the journal Cancers, breast cancer is the most common invasive type of cancer in women,…

Trodelvy Approved for Heavily Pre-treated TNBC Patients in US

Trodelvy Approved for Heavily Pre-treated TNBC Patients in US

The U.S. Food and Drug Administration (FDA) has approved Immunomedics’ antibody-drug conjugate Trodelvy (sacituzumab govitecan) to treat triple-negative breast cancer (TNBC) patients who already tried at least two previous therapies for metastatic disease. The approval, given under FDA’s Accelerated Approval Program and about five weeks ahead of an expected decision, makes Trodelvy the first antibody-drug conjugate available for hard-to-treat…

Xoft Single-Dose Radiation Therapy for Early-Stage Breast Cancer Shows Continuing Promise

Xoft Single-Dose Radiation Therapy for Early-Stage Breast Cancer Shows Continuing Promise

iCAD Inc., a company that delivers innovative cancer detection and radiation therapy solutions, recently presented updated clinical data on the use of intraoperative radiation therapy (IORT) with the Company’s Xoft Axxent Electronic Brachytherapy System to treat patients with early-stage breast cancer at the San Antonio Breast Cancer Symposium held in December in San Antonio, Texas. Management of Nashua, New…